Efficacy of autologous bone marrow mononuclear cells plus mesenchymal stem cell versus autologous bone marrow mononuclear cell alone in ischemic foot ulcer

Cytotherapy ◽  
2014 ◽  
Vol 16 (4) ◽  
pp. S77-S78
Author(s):  
H. Harunarashid ◽  
M. Mohd Idris ◽  
F. Mohamad Yusoff ◽  
S. Chin ◽  
S. Shahari ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Mononuclear Cells ◽  
Foot Ulcer ◽  
Autologous Bone Marrow ◽  
Bone Marrow Mononuclear Cell ◽  
Bone Marrow Mononuclear Cells ◽  
Autologous Bone ◽  
Cell Versus

Intramyocardial administration of autologous bone marrow mononuclear cells in a critically ill child with dilated cardiomyopathy

2010 ◽  
Vol 21 (1) ◽  
pp. 110-112 ◽  
Author(s):  
Aris Lacis ◽  
Andrejs Erglis
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Dilated Cardiomyopathy ◽  
Cell Transplantation ◽  
Critically Ill ◽  
Mononuclear Cells ◽  
Autologous Bone Marrow ◽  
Bone Marrow Mononuclear Cells ◽  
Autologous Bone

AbstractAlmost half of the children with symptomatic dilated cardiomyopathy receive a transplant or die within 2 years; however, cardiac stem cell transplantation has become a promising therapeutic option. The present case demonstrates for the first time, to our knowledge, the intramyocardial administration of autologous bone marrow mononuclear cells in a critically ill 4-month-old child with severe dilated cardiomyopathy. Left ventricular ejection fraction increased from 20% before stem cell transplantation to 41% at 4 months of follow-up.

scholarly journals NeuroRegen Scaffolds Combined with Autologous Bone Marrow Mononuclear Cells for the Repair of Acute Complete Spinal Cord Injury: A 3-Year Clinical Study

2020 ◽  
Vol 29 ◽  
pp. 096368972095063
Author(s):  
Wugui Chen ◽  
Ying Zhang ◽  
Sizhen Yang ◽  
Jing Sun ◽  
Hao Qiu ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Spinal Cord Injury ◽  
Stem Cell ◽  
Mononuclear Cells ◽  
Autologous Bone Marrow ◽  
Bone Marrow Mononuclear Cells ◽  
Cord Injury ◽  
Autologous Bone

Spinal cord injury (SCI) remains among the most challenging pathologies worldwide and has limited therapeutic possibilities and a very bleak prognosis. Biomaterials and stem cell transplantation are promising treatments for functional recovery in SCI. Seven patients with acute complete SCI diagnosed by a combination of methods were included in the study, and different lengths (2.0–6.0 cm) of necrotic spinal cord tissue were surgically cleaned under intraoperative neurophysiological monitoring. Subsequently, NeuroRegen scaffolds loaded with autologous bone marrow mononuclear cells (BMMCs) were implanted into the cleaned site. All patients participated in 6 months of rehabilitation and at least 3 years of clinical follow-up. No adverse symptoms associated with stem cell or functional scaffold implantation were observed during the 3-year follow-up period. Additionally, partial shallow sensory and autonomic nervous functional improvements were observed in some patients, but no motor function recovery was observed. Magnetic resonance imaging suggested that NeuroRegen scaffold implantation supported injured spinal cord continuity after treatment. These findings indicate that implantation of NeuroRegen scaffolds combined with stem cells may serve as a safe and promising clinical treatment for patients with acute complete SCI. However, determining the therapeutic effects and exact application methods still requires further study.

scholarly journals Repeated Autologous Bone Marrow-Derived Mesenchymal Stem Cell Injections Improve Radiation-Induced Proctitis in Pigs

2013 ◽  
Vol 2 (11) ◽  
pp. 916-927 ◽  
Author(s):  
Christine Linard ◽  
Elodie Busson ◽  
Valerie Holler ◽  
Carine Strup-Perrot ◽  
Jean-Victor Lacave-Lapalun ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Autologous Bone Marrow ◽  
Radiation Induced ◽  
Autologous Bone

scholarly journals Mycobacterium tuberculosisContaminant Risk on Bone Marrow Aspiration Material from Iliac Bone Patients with Active Tuberculous Spondylitis

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Ahmad Jabir Rahyussalim ◽  
Tri Kurniawati ◽  
Andriansjah Rukmana
Keyword(s):  
Bone Marrow ◽  
Mycobacterium Tuberculosis ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Bacterial Culture ◽  
Autologous Bone Marrow ◽  
Iliac Bone ◽  
Tuberculous Spondylitis ◽  
Autologous Bone ◽  
Pcr Test

There was a concern onMycobacterium tuberculosisspreading to the bone marrow, when it was applied on tuberculous spine infection. This research aimed to study the probability of using autologous bone marrow as a source of mesenchymal stem cell for patients with tuberculous spondylitis. As many as nine patients with tuberculous spondylitis were used as samples. During the procedure, the vertebral lesion material and iliac bone marrow aspirates were obtained for acid fast staining, bacteria culture, and PCR (polymerase chain reaction) tests forMycobacterium tuberculosisat the Clinical Microbiology Laboratory of Faculty of Medicine Universitas Indonesia. This research showed that there was a relationship between diagnostic confirmation of tuberculous spondylitis based on the PCR test and bacterial culture on the solid vertebral lesion material with the PCR test and bacterial culture from the bone marrow aspirates. If the diagnostic confirmation concluded positive results, then there was a higher probability that there would be a positive result for the bone marrow aspirates, so that it was not recommended to use autologous bone marrow as a source of mesenchymal stem cell for patients with tuberculous spondylitis unless the PCR and culture examination of the bone marrow showed a negative result.

scholarly journals Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support

Blood ◽  
1992 ◽  
Vol 80 (7) ◽  
pp. 1666-1672
Author(s):  
S Jagannath ◽  
DH Vesole ◽  
L Glenn ◽  
J Crowley ◽  
B Barlogie
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Mononuclear Cells ◽  
Intensive Therapy ◽  
Autologous Bone Marrow ◽  
Blood Stem Cell ◽  
High Dose ◽  
Platelet Recovery ◽  
Gm Csf ◽  
Autologous Bone

To improve the safety of autotransplantation for myeloma, peripheral blood stem cell (PBSC) collection was attempted in 75 previously treated patients after the administration of high-dose cyclophosphamide (HD-CTX; 6 g/m2) with or without granulocyte-macrophage colony- stimulating factor (GM-CSF). Sixty patients subsequently received melphalan 200 mg/m2 (57 patients) or melphalan 140 mg/m2 and total body irradiation (850 cGy) (3 patients) supported by both autologous bone marrow and PBSC; 38 patients received GM-CSF posttransplantation. Among 72 patients undergoing PBSC apheresis, “good” mobilization (greater than 50 colony-forming units granulocyte-macrophage [CFU-GM] per 10(5) mononuclear cells) was achieved when prior chemotherapy did not exceed 1 year and when GM-CSF was used post-HD-CTX; similarly, rapid platelet recovery to 50,000/microL within 2 weeks was associated with “good” PBSC mobilization. These same variables also predicted for rapid engraftment after autotransplantation, so that hematologic recovery (granulocytes greater than 500/microL and platelets greater than 50,000/microL) proceeded within 2 weeks among the 37 patients with “good” PBSC collection. As a result of rapid neutrophil recovery (greater than 500/microL) within a median of 2 weeks, infectious complications both post-HD-CTX and posttransplant were readily manageable, resulting in only one treatment-related death post-HD-CTX. The cumulative response rate (greater than or equal to 75% cytoreduction) for all 75 patients was 68%, with 12-month event-free and overall survival projections of about 85%. Using both bone marrow and PBSC together with GM-CSF, autotransplants are safe and appear effective in myeloma, especially when prior therapy had been limited to less than 1 year. More than 80% of transplanted patients achieved complete hematologic recovery within a median of 1 month posttransplant (granulocytes greater than 1,500/microL; platelets greater than 100,000/microL; hemoglobin greater than 10 g%), thus providing sufficient hematopoietic reserve for further chemotherapy in the event of posttransplant relapse.

Sign in / Sign up

Export Citation Format

Share Document